Roth Capital lowered the firm’s price target on Biofrontera Inc. (BFRI) to $9 from $10 and keeps a Buy rating on the shares. The firm is updating its model with higher cost of goods sold to reflect the impact of tariffs, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BFRI:
- Biofrontera Approves Key Proposals at Special Meeting
- Biofrontera says last patient completes treatment in Phase 3 study of Ameluz
- Biofrontera, Inc. Reports Record Sales Amid Strategic Growth
- Biofrontera announces last-patient-out in Phase 2b study of Ameluz topical gel
- Biofrontera Inc. Reports Revenue Growth Amid Strategic Restructuring